- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05881031
Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity
Single Site Feasibility and Safety Study of Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Children with medical complexity (CMC) are increasingly prescribed noninvasive positive pressure ventilation (NiPPV) for chronic respiratory failure. In our clinical experience, patients and families would prefer NiPPV initiation in the home environment but this is not standard of care. This proposal will evaluate the feasibility and safety of an innovative model of care for NiPPV initiation in the home environment utilizing remote telemonitoring compared to usual care which is in-hospital polysomnography (PSG) laboratory-based initiation.
The incidence of CMC requiring NiPPV is exponentially growing. NiPPV effectively corrects abnormal gas exchange, improves sleep quality, and reduces symptoms of chronic respiratory failure. The use of NiPPV has been associated with increased survival and improved health-related quality of life (HRQOL). To ensure effectiveness, NiPPV must be used for all periods of sleep and settings must be individually-titrated. Unfortunately, poor adherence results in many CMC being undertreated for chronic respiratory failure. Successful NiPPV initiation is critical because early negative experiences are commonly reported barriers to adherence6 and early usage predicts longer term use. Standard of care is the initiation and titration of NiPPV during a one-night in-hospital PSG. A PSG is challenging for CMC and families due to their medical fragility and lasting effects of travel and a disrupted routine, the significant amount of equipment and supplies that must be brought to the study as well as the financial implications and additional psychosocial stress for caregivers. In addition, negative experiences with NiPPV may be exacerbated by introduction of the therapy in an unfamiliar PSG laboratory with burdensome monitoring. Furthermore, a one-night PSG provides limited sleep data that may not be representative of dynamic and variable sleeping patterns that occur in the comfort of one's home.
Recent technological advances in remote NiPPV monitoring coupled with a shift to virtual care models has enabled a patient and family centered opportunity to bypass the PSG laboratory and initiate NiPPV at home. Remote NiPPV monitoring extends data collection beyond discrete health care encounters and provides real-time data on adherence and efficacy that can be wirelessly transmitted to facilitate setting adjustment by clinicians. Home NiPPV initiation is increasingly being requested by patients and caregivers. The potential benefits of this innovative care model include increasing patient and family empowerment, improving the delivery of high quality patient-centred care at home, and optimizing NiPPV use. Although there is growing data in the adult population to support home NiPPV initiation via telemonitoring, this cannot be simply extrapolated to CMC. There are key differences in the etiology and manifestation of chronic respiratory failure in CMC compared to adults. Furthermore, family caregivers play an important role in NiPPV acceptance and adherence.
Canadian guidelines acknowledge the lack of evidence for the setting in which NiPPV is initiated. Home NiPPV initiation in CMC is a novel model of care that may result in large health system impacts, but requires a feasibility study before embarking on a large-scale trial.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Munazzah Ambreen, MSc
- Phone Number: 328361 (416) 813-7654
- Email: munazzah.ambreen@sickkids.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- Recruiting
- The Hospital for Sick Children
-
Contact:
- Munazzah Ambreen, MSc
- Phone Number: 328361 (416) 813-7654
- Email: munazzah.ambreen@sickkids.ca
-
Principal Investigator:
- Reshma Amin, MD MSc
-
Principal Investigator:
- Lena Xiao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 5-17 years old
- Newly prescribed NiPPV
- Tolerated awake NiPPV trial
- Provides informed consent
Exclusion Criteria:
- Cardiac disease at risk of hemodynamic instability with NiPPV initiation (eg cardiac dysfunction (ejection fraction <45%), pulmonary hypertension (mean pulmonary artery pressure ≥ 20 mmHg on right heart catheterization or suggestive echocardiogram findings in the opinion of a pediatric cardiologist), or single ventricle)
- At high risk of complications with NiPPV in the opinion of the child's physician (eg pneumothorax and aspiration risk)
- Severe sleep disordered breathing with peak CO2 ≥ 60mmHg or apnea-hypopnea index (AHI)≥ 30/hr (AHI measures the number of respiratory events per hour)
- Participation in concurrent research study that may affect NiPPV adherence (proposed primary outcome of full study)
- Exclusion of study participants if the caregiver or participant is not English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of care
Standard of care is NiPPV initiation during a one-night, in-hospital PSG, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines.
Once NiPPV equipment is obtained and NiPPV is used at home (time 0), NiPPV setting changes may occur at 1, 4, and 12 weeks when participants are contacted by the respiratory therapist.
Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care.
|
|
Experimental: Home Initiation of NiPPV
NiPPV settings will be titrated during an awake NiPPV trial by the respiratory therapist.
Once NiPPV equipment is obtained and NiPPV is used at home (time 0), further titration of the NiPPV settings will occur on an outpatient basis guided by remote telemonitoring and home overnight oximetries at 1, 4, and 12 weeks.
Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care.
Participants will complete an in-hospital PSG after 12 weeks, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines.
|
Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment and retention rate
Time Frame: 2 years
|
Feasibility outcome. The recruitment rate is the proportion of eligible people recruited to the trial. This is the number of people randomised divided by the number of people eligible. The retention rate is the proportion of randomised people who complete follow up at 3 months (end of trial). |
2 years
|
Proportion of eligible patients randomized
Time Frame: 2 years
|
Feasibility outcome.
Proportion of eligible participants who are recruited to the study and randomized
|
2 years
|
Proportion of patients that crossover based on safety criteria
Time Frame: 2 years
|
Safety outcome.
Proportion of patients in the intervention arm who crossover to the control arm based on pre-specified monitoring criteria
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean minutes of nightly NiPPV usage
Time Frame: 12 weeks
|
Proposed trial outcome.
Adherence will be determined adjectively using ventilator download data.
|
12 weeks
|
Proxy-reported Psychological Scale (percentage rank)
Time Frame: 12 weeks
|
Proposed trial outcome.
The proxy-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The percentage rank range is 0-100, with lower scores indicating a "dissatisfaction with life".
|
12 weeks
|
Proxy-reported Psychological Scale (percentage rank)
Time Frame: 4 weeks
|
Proposed trial outcome.
The proxy-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The percentage rank range is 0-100, with lower scores indicating a "dissatisfaction with life".
|
4 weeks
|
Proxy-reported Psychological Scale (T-value)
Time Frame: 12 weeks
|
Proposed trial outcome.
The proxy-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The T-values have a mean of 50 and standard deviation of 10.
Higher T-values indicate a higher quality of life.
|
12 weeks
|
Proxy-reported Psychological Scale (T-value)
Time Frame: 4 weeks
|
Proposed trial outcome.
The proxy-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The T-values have a mean of 50 and standard deviation of 10.
Higher T-values indicate a higher quality of life.
|
4 weeks
|
Self-Reported Psychological Scale (percentage rank)
Time Frame: 12 weeks
|
Proposed trial outcome.
The self-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The percentage rank range is 0-100, with lower scores indicating a "dissatisfaction with life".
|
12 weeks
|
Self-Reported Psychological Scale (percentage rank)
Time Frame: 4 weeks
|
Proposed trial outcome.
The self-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The percentage rank range is 0-100, with lower scores indicating a "dissatisfaction with life".
|
4 weeks
|
Self-Reported Psychological Scale (T-value)
Time Frame: 12 weeks
|
Proposed trial outcome.
The self-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The T-values have a mean of 50 and standard deviation of 10.
Higher T-values indicate a higher quality of life.
|
12 weeks
|
Self-Reported Psychological Scale (T-value)
Time Frame: 4weeks
|
Proposed trial outcome.
The self-reported Psychological Scale from the KIDSCREEN-52 questionnaire will be used.
The T-values have a mean of 50 and standard deviation of 10.
Higher T-values indicate a higher quality of life.
|
4weeks
|
Caregiver reported Sense of Mastery
Time Frame: 12 weeks
|
Proposed trial outcome.
The Pearlin Mastery Scale will be used to measure parental mastery.
Scores range from 7 to 28, with higher scores indicating greater levels of mastery.
|
12 weeks
|
Caregiver reported Sense of Mastery
Time Frame: 4 weeks
|
Proposed trial outcome.
The Pearlin Mastery Scale will be used to measure parental mastery.
Scores range from 7 to 28, with higher scores indicating greater levels of mastery.
|
4 weeks
|
Patient and family study experience, preference of intervention and barriers
Time Frame: 12 weeks
|
Feasibility and acceptability outcome.
Based on optional qualitative interview with participant and/or caregiver after completion of study procedures.
|
12 weeks
|
Difference in expiratory positive airway pressure based on home NiPPV titration and PSG titration in the intervention arm
Time Frame: 12 weeks
|
Safety outcome.
Comparison of final NiPPV settings at 12 weeks in the intervention arm and PSG prescribed NiPPV settings at 12 weeks and beyond.
|
12 weeks
|
Difference in inspiratory positive airway pressure based on home NiPPV titration and PSG titration in the intervention arm
Time Frame: 12 weeks
|
Safety outcome.
Comparison of final NiPPV settings at 12 weeks in the intervention arm and PSG prescribed NiPPV settings at 12 weeks and beyond.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000080480
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep-Disordered Breathing
-
Assistance Publique - Hôpitaux de ParisRecruitingSleep-disordered Breathing (SDB)France
-
Wayne State UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedSleep-disordered BreathingUnited States
-
University Hospital, AntwerpCompleted
-
Brigham and Women's HospitalChildren's Hospital of Philadelphia; University of Michigan; Boston Children's... and other collaboratorsCompleted
-
Assiut UniversityUnknownObstructive Sleep Disordered BreathingEgypt
-
The Cleveland ClinicWithdrawnObstructive Sleep Disordered BreathingUnited States
-
Merz Pharmaceuticals GmbHWithdrawn
-
Beijing Children's HospitalMerck Sharp & Dohme LLCUnknownSleep-disordered BreathingChina
-
National Center for Research Resources (NCRR)CompletedSleep-Disordered BreathingUnited States
-
Belun Technology Company LimitedUniversity Hospitals Cleveland Medical CenterNot yet recruitingArrhythmia | Sleep-Disordered Breathing | Sleep Architecture
Clinical Trials on Home Initiation of NiPPV
-
IP Santé DomicileUnknown
-
University Medical Center GroningenCompletedNeuromuscular Diseases | Respiration, Artificial | Noninvasive Ventilation | Cost-Benefit Analysis | Positive-Pressure Respiration | Respiratory Therapy | Ambulatory MonitoringNetherlands
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; Kamuzu University of Health... and other collaboratorsCompleted
-
University Medical Center GroningenCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV | ARTSouth Africa, Uganda
-
London School of Hygiene and Tropical MedicineUniversity College, London; World Health Organization; UNITAID; Liverpool School... and other collaboratorsCompleted
-
University of FloridaNational Institute of Nursing Research (NINR)CompletedBreast Milk ExpressionUnited States
-
Temple UniversityCompletedDiabetic RetinopathyUnited States
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University of California, San FranciscoCompletedAbortionUnited States